The best indicator for Idexx Laboratories (IDXX)
We backtested 20 indicators across daily, weekly and hourly charts on real Idexx Laboratories (IDXX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
CCI
On the daily chart, this is the strongest risk-adjusted edge we found for Idexx Laboratories (IDXX) over ~34.9 years — trailing buy-and-hold by 7.5% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | CCI ✓ | Daily | 12.6% | 0.61 | -48.9% | 76.5% | 170 | -7.5% |
| 2 | Holy Grail Confluence ✓ | Daily | 11.3% | 0.61 | -49.7% | 77.1% | 48 | -8.8% |
| 3 | Williams %R ✓ | Daily | 12.0% | 0.59 | -40.3% | 74.3% | 226 | -8.1% |
| 4 | Money Flow Index ✓ | Daily | 12.1% | 0.59 | -58.2% | 83.3% | 42 | -7.9% |
| 5 | EMA 20/50 Cross ✓ | Weekly | 13.3% | 0.57 | -70.9% | 46.7% | 15 | -6.7% |
| 6 | Bollinger Breakout ✓ | Weekly | 10.1% | 0.55 | -70.6% | 52.9% | 34 | -9.8% |
| 7 | EMA 50/200 Cross ✓ | Daily | 12.2% | 0.54 | -74.3% | 47.4% | 19 | -7.8% |
| 8 | Stochastic ✓ | Daily | 10.0% | 0.52 | -70.6% | 73.9% | 180 | -10.1% |
| 9 | EMA 20/50 Cross ✓ | Daily | 10.8% | 0.51 | -71.2% | 43.4% | 76 | -9.3% |
| 10 | RSI Trend (>50) ✓ | Weekly | 10.7% | 0.5 | -72.3% | 49.0% | 96 | -9.3% |
| 11 | Rate of Change ✓ | Weekly | 10.9% | 0.5 | -59.2% | 45.0% | 109 | -9.1% |
| 12 | EMA-10 Trend ✓ | Weekly | 10.5% | 0.5 | -57.9% | 46.5% | 157 | -9.4% |
| 13 | SMA 50/200 Cross ✓ | Daily | 10.2% | 0.48 | -69.7% | 64.3% | 28 | -9.9% |
| 14 | Stochastic ✓ | Weekly | 7.7% | 0.48 | -41.3% | 86.7% | 30 | -12.2% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Idexx Laboratories (IDXX), CCI on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.